The global syphilis immunoassay diagnostics market is witnessing steady expansion, driven by the increasing prevalence of syphilis, growing awareness of sexually transmitted infections (STIs), and rising demand for rapid and accessible diagnostic solutions. The market was valued at approximately US$ 548.5 Mn in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2034, reaching nearly US$ 978.5 Mn by 2034.

Analysts’ Viewpoint

Analysts consider the syphilis immunoassay diagnostics industry a dynamic market with substantial growth potential. Increasing syphilis infections worldwide are encouraging governments and healthcare organizations to strengthen screening and prevention programs. Greater awareness of STIs is also prompting individuals to seek early testing and diagnosis.

Technological advancements, particularly in point-of-care (POC) and rapid testing, are improving the accessibility and speed of syphilis diagnosis. Leading companies such as Abbott and Roche Diagnostics are focusing on product innovation, including multiplex assays capable of detecting multiple infections. Nevertheless, stringent regulatory requirements and limited diagnostic access in low-income regions remain key challenges.

Emerging markets and the integration of digital health technologies are expected to create additional opportunities by improving testing accessibility, patient monitoring, and healthcare delivery.

Product Innovation Driving Market Growth

The increasing number of product launches is expected to significantly contribute to market growth. New-generation syphilis immunoassay products offer improved sensitivity, specificity, convenience, and faster results, increasing their adoption across healthcare settings.

In February 2023, Mylab Discovery Solutions announced the expansion of its rapid STI testing portfolio with a Syphilis Antibody test designed to detect IgG, IgA, and IgM antibodies to Treponema pallidum. Its room-temperature storage and point-of-care design make the test particularly suitable for resource-limited environments.

The trend toward self-testing and at-home diagnostics is also creating new growth opportunities. In 2023, Simple HealthKit launched an at-home syphilis testing kit, offering consumers a convenient and private option for testing.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=Srep_id=2140

Rising Syphilis Prevalence Creates Strong Demand

The growing prevalence of syphilis remains one of the major drivers of the global diagnostics market. According to WHO data published in 2023, new syphilis cases among adults aged 15–49 years increased by 30% between 2020 and 2022 in North America. More than 3,700 congenital syphilis cases were reported in the U.S. in 2022, representing a substantial increase over the previous decade.

Similarly, the European Centre for Disease Prevention and Control reported 35,391 confirmed syphilis cases across 29 EU/EEA Member States in 2022. The notification rate increased by 34% compared with 2021.

These trends are increasing demand for reliable diagnostics in STI clinics, prenatal care facilities, community health centers, and other high-risk healthcare settings.

Kits Reagents Segment to Maintain Dominance

The kits and reagents segment is expected to remain a major contributor to market revenue. Growing demand for rapid and accurate diagnosis, technological advancements in immunoassays, and increasing adoption of POC and rapid diagnostic tests are supporting segment growth.

Point-of-Care Testing Gains Momentum

Point-of-care testing is gaining prominence because it enables healthcare professionals to obtain results rapidly and initiate treatment without lengthy laboratory procedures. This is particularly valuable in remote and resource-limited areas.

In September 2022, Chembio Diagnostics received a US$ 3.2 Mn CDC contract to develop and clinically validate a rapid POC syphilis test based on its Dual Path Platform technology. The proposed assay was designed to detect treponemal and nontreponemal antibodies and deliver results in less than 20 minutes.

Regional Outlook

North America is expected to remain a leading regional market, supported by government initiatives aimed at controlling the rising syphilis burden. Significant funding for rapid testing and congenital syphilis prevention is strengthening diagnostic infrastructure and adoption.

Competitive Landscape

Major companies operating in the syphilis immunoassay diagnostics market include Abbott, BD, bioMérieux, Bio-Rad Laboratories, Chembio Diagnostics, Danaher, DiaSorin, Roche Diagnostics, Fujirebio, QuidelOrtho, Siemens Healthineers, Thermo Fisher Scientific, and Trinity Biotech.

Recent developments, including Roche's acquisition of LumiraDx technology and Labcorp's expansion of its OTC syphilis testing portfolio, highlight the industry's shift toward rapid, decentralized, and consumer-accessible diagnostics.

Overall, rising disease prevalence, product innovation, government initiatives, funding, and growing adoption of POC and self-testing solutions are expected to sustain the growth of the global syphilis immunoassay diagnostics market through 2034.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453